(Q34448244)

2 August 2017

1 reference

title

Pharmacologic preservation of the hemostatic system during cardiac surgery (English)

1 reference

2 August 2017

0 references

Levy JH

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

The Annals of Thoracic Surgery

2 August 2017

published in

1 reference

2 August 2017

volume

72

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

S1814-20

1 reference

Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Molecular and cellular biology of blood coagulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Thrombin hypothesis of thrombus generation and vascular lesion formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

The coagulation cascade: initiation, maintenance, and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Antithrombotic agents in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Aprotinin and the systemic inflammatory response after cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Thrombin-mediated events implicated in mast cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Low-molecular-weight heparins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Low-molecular-weight heparins: an intriguing new twist with profound implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Novel intravenous antithrombins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Effects of protamine on histamine release from human lung.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Uses of antithrombin III concentrate in congenital and acquired deficiency states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Clinical outcomes of bivalirudin for ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Anticoagulants in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Thrombin inhibitors as anticoagulant agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Heparinless cardiopulmonary bypass with ancrod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Pharmacokinetics of aprotinin in preoperative cardiac surgical patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Clopidogrel: a review of its use in the prevention of atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903218-0

10.1016/S0003-4975(01)03218-0

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference